Cara Therapeutics Inc

NASDAQ:CARA   4:00:00 PM EDT
4.89
-0.19 (-3.74%)
7:49:07 PM EDT: $4.90 +0.01 (+0.20%)
Products

Cara Therapeutics Submits New Drug Application to U.S. FDA for KORSUVA Injection in Hemodialysis Patients

Published: 12/28/2020 12:09 GMT
Cara Therapeutics Inc (CARA) - Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Korsuva™ Injection in Hemodialysis Patients With Moderate-to-severe Pruritus.
Cara Therapeutics Inc - NDA Submission Includes Request for Priority Review Under Breakthrough Therapy Designation for Korsuva Injection.
Cara Therapeutics Inc - Has Requested Priority Review for NDA Which, If Granted, Could Result in Six-month Review Process.